117 related articles for article (PubMed ID: 1902292)
1. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Keer HN; Gaylis FD; Kozlowski JM; Kwaan HC; Bauer KD; Sinha AA; Wilson MJ
Prostate; 1991; 18(3):201-14. PubMed ID: 1902292
[TBL] [Abstract][Full Text] [Related]
2. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Lyon PB; See WA; Xu Y; Cohen MB
Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Gaylis FD; Keer HN; Wilson MJ; Kwaan HC; Sinha AA; Kozlowski JM
J Urol; 1989 Jul; 142(1):193-8. PubMed ID: 2659823
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2011 Dec; 26(6):1407-13. PubMed ID: 21874261
[TBL] [Abstract][Full Text] [Related]
6. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Wilson MJ; Sinha AA
Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
9. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynold LM
Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
[TBL] [Abstract][Full Text] [Related]
10. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
12. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
Hoosein NM; Boyd DD; Hollas WJ; Mazar A; Henkin J; Chung LW
Cancer Commun; 1991 Aug; 3(8):255-64. PubMed ID: 1653586
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Takai S; Yamamura M; Tanaka K; Kawanishi H; Tsuji M; Nakane Y; Hioki K; Yamamoto M
Int J Cancer; 1991 Apr; 48(1):20-7. PubMed ID: 1902201
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats.
Andreasen PA; Kristensen P; Lund LR; Danø K
Endocrinology; 1990 May; 126(5):2567-76. PubMed ID: 2109689
[TBL] [Abstract][Full Text] [Related]
15. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
16. Prevention of metastasis by inhibition of the urokinase receptor.
Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Forbes K; Gillette K; Kelley LA; Sehgal I
World J Urol; 2004 Apr; 22(1):67-71. PubMed ID: 15052500
[TBL] [Abstract][Full Text] [Related]
18. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
19. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
